New Two-Drug attack on Tough-to-Treat cancers begins human testing
NCT ID NCT06975293
Summary
This early-stage trial is testing the safety and initial effectiveness of a new oral drug, STC-15, when given alongside an existing immunotherapy called toripalimab. It will enroll about 188 adults with specific advanced cancers—including lung, melanoma, endometrial, and head/neck cancers—that have worsened despite prior treatments. The main goals are to find a safe dose and see if the combination can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwell Health Cancer Institute
RECRUITINGLake Success, New York, 11042, United States
Contact Email: •••••@•••••
Contact
-
The START Center
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.